Skip to content
Post-Activity Test and Activity Evaluation
POST TEST
*
1.
According to the Centers for Disease Control and Prevention 2019 list of priority pathogens, which of the following Gram-negative pathogens is not included as an urgent or serious threat?
(Required.)
Carbapenem-resistant Enterobacteriaceae (Enterobacterales)
MDR
Pseudomonas aeruginosa
Carbapenem-resistant
Stenotrophomonas maltophilia
ESBL-producing Enterobacteriaceae (Enterobacterales)
*
2.
Ceftolozane-tazobactam exhibits the greatest in vitro activity against which of the following pathogens?
(Required.)
KPC-producing
Klebsiella pneumoniae
MDR
Pseudomonas aeruginosa
Carbapenem-resistant
Acinetobacter baumannii
NDM-producing
Escherichia coli
*
3.
Which of the following newer antimicrobials exhibits the greatest in vitro activity against
Acinetobacter baumannii
?
(Required.)
Ceftazidime-avibactam
Ceftolozane-tazobactam
Imipenem-relebactam
Cefiderocol
*
4.
Ceftazidime-avibactam exhibits in vitro activity against Enterobacterales that produce all of the following beta-lactamases except:
(Required.)
KPC
OXA-48
NDM
AmpC
*
5.
For a patient without impaired or augmented renal function, which of the following antimicrobial agents requires intravenous dosing every 6 hours?
(Required.)
Ceftazidime-avibactam
Ceftolozane-tazobactam
Imipenem-relebactam
Cefiderocol
